Since FAP expression in ovarian cancers was shown to be associated with cancer promotion, invasion, chemoresistance, and worse clinical outcomes, it is not surprising that FAP theranostics have been suggested as potential adjuvants to existing treatment paradigms20,138,139. Here, FAP is linked to ovarian carcinoma.